Andrew JHL Snelling

Featured in: Favicon

Articles

Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study - Communications Medicine

Jan 16, 2025 | nature.com | Aziz Sheikh |Andrew JHL Snelling

AbstractSotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains insufficient.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.